High Plasma Fibrinogen is Correlated With Poor Response to Trastuzumab Treatment in HER2 Positive Breast Cancer
| Autor: | Qiang Wang, Wei Zhang, Bao-Quan Hu, You-Ran Ji, Yu Xia, Qing Lu, Ji-Wei Liang, Jun Wang, Yu-Lin Liu, Fang-Fang Shang, Bing Liang |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Oncology Pathology medicine.medical_specialty Receptor ErbB-2 Observational Study Antineoplastic Agents Breast Neoplasms Kaplan-Meier Estimate Antibodies Monoclonal Humanized Fibrinogen Article Disease-Free Survival Fibrin Fibrinogen Degradation Products Breast cancer Trastuzumab HER2 Positive Breast Cancer Internal medicine medicine Humans skin and connective tissue diseases Retrospective Studies Prothrombin time medicine.diagnostic_test business.industry Retrospective cohort study General Medicine Middle Aged Prognosis medicine.disease Coagulation ComputingMethodologies_DOCUMENTANDTEXTPROCESSING Prothrombin Time Female Partial Thromboplastin Time business medicine.drug Partial thromboplastin time |
| Zdroj: | Medicine |
| ISSN: | 0025-7974 |
| DOI: | 10.1097/md.0000000000000481 |
| Popis: | Supplemental Digital Content is available in the text Some of HER-2 positive breast cancer patients failed to trastuzumab treatment. Recent reports have indicated the correlation between plasma coagulation parameters and clinical characteristics in breast cancer. The aim of this study was to analyze the role of coagulation parameters in trastuzumab treated patients. Coagulation parameters from trastuzumab treated breast cancer patients were retrospectively studied from 2006 to 2010. The correlation between routine coagulation levels and clinical characteristics were analyzed, including prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (Fib) and D-dimer (DD). The Kaplan–Meier analysis and Cox regression hazard model were applied to assess their effect on prognosis. Totally 102 hospitalized breast cancer patients who received trastuzumab were collected and followed-up. All patients were HER-2 positive advanced breast cancer, with a median age of 45 years old. Extended PT, APTT, and TT were found in trastuzumab treatment non-effective group, as well as increased Fib and DD. But significant increase was only found in Fib. High Fib status (Fib > 2.88 g/L) was correlated with clinical characteristics, such as pathological grade, and reversely correlated with PTEN expression. More importantly, poor disease-free survival (DFS) and overall survival (OS) to trastuzumab treatment were found in high Fib breast cancer patients. This retrospective study suggests high Fib status was correlated with poor treatment response to trastuzumab. Our findings indicated that Fib > 2.88 should alert physicians to consider a pretreatment for reducing Fib levels before trastuzumab treatment in HER-2 positive breast cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|